Gene therapy advances: a meta-analysis of AAV usage in clinical settings

HKE Au, M Isalan, M Mielcarek - Frontiers in medicine, 2022 - frontiersin.org
Adeno-associated viruses (AAVs) are the safest and most effective gene delivery vehicles to
drive long-term transgene expression in gene therapy. While animal studies have shown …

Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects

H Li, Y Yang, W Hong, M Huang, M Wu… - Signal transduction and …, 2020 - nature.com
Based on engineered or bacterial nucleases, the development of genome editing
technologies has opened up the possibility of directly targeting and modifying genomic …

Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities

SJ Tabrizi, MD Flower, CA Ross, EJ Wild - Nature Reviews Neurology, 2020 - nature.com
Huntington disease (HD) is a neurodegenerative disease caused by CAG repeat expansion
in the huntingtin gene (HTT) and involves a complex web of pathogenic mechanisms …

An RNA-targeting CRISPR–Cas13d system alleviates disease-related phenotypes in Huntington's disease models

KH Morelli, Q Wu, ML Gosztyla, H Liu, M Yao… - Nature …, 2023 - nature.com
Huntington's disease (HD) is a fatal, dominantly inherited neurodegenerative disorder
caused by CAG trinucleotide expansion in exon 1 of the huntingtin (HTT) gene. Since the …

[HTML][HTML] Huntingtin lowering strategies for disease modification in Huntington's disease

SJ Tabrizi, R Ghosh, BR Leavitt - Neuron, 2019 - cell.com
Huntington's disease is caused by an abnormally expanded CAG repeat expansion in the
HTT gene, which confers a predominant toxic gain of function in the mutant huntingtin …

Editing the epigenome: technologies for programmable transcription and epigenetic modulation

PI Thakore, JB Black, IB Hilton, CA Gersbach - Nature methods, 2016 - nature.com
Gene regulation is a complex and tightly controlled process that defines cell identity, health
and disease, and response to pharmacologic and environmental signals. Recently …

Therapies targeting DNA and RNA in Huntington's disease

EJ Wild, SJ Tabrizi - The Lancet Neurology, 2017 - thelancet.com
No disease-slowing treatment exists for Huntington's disease, but its monogenic inheritance
makes it an appealing candidate for the development of therapies targeting processes close …

Current and possible future therapeutic options for Huntington's disease

MW Ferguson, CJ Kennedy… - Journal of central …, 2022 - journals.sagepub.com
Huntington's disease (HD) is an autosomal neurodegenerative disease that is characterized
by an excessive number of CAG trinucleotide repeats within the huntingtin gene (HTT). HD …

CRISPR/Cas9 editing of the mutant huntingtin allele in vitro and in vivo

AM Monteys, SA Ebanks, MS Keiser, BL Davidson - Molecular therapy, 2017 - cell.com
Huntington disease (HD) is a fatal dominantly inherited neurodegenerative disorder caused
by CAG repeat expansion (> 36 repeats) within the first exon of the huntingtin gene …

Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease

B Zeitler, S Froelich, K Marlen, DA Shivak, Q Yu, D Li… - Nature medicine, 2019 - nature.com
Huntington's disease (HD) is a dominantly inherited neurodegenerative disorder caused by
a CAG trinucleotide expansion in the huntingtin gene (HTT), which codes for the pathologic …